CDC investigating 5 hospitalizations in people 65+ for cardiac/neurologic events after receiving Valneva's Ixchiq chikungunya ...

More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...

John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...

Teladoc reports $1B net loss in 2024, including $790M impairment charge for BetterHelp. Revenue down 1% to $2.7B, shares fall ...

Color Health and OpenAI partnered with UCSF to develop an AI copilot for cancer screenings, publishing architecture details ...

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native ...

Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...

Hansoh exits siRNA deal with Silence Therapeutics, Vir seeks partner for hep B combo, Alopexx plans IPO, Medigene-EpimAb partner on T cell engagers, Belite Bio trial cleared ...

Merck, Granules India, Bavarian Nordic lead manufacturing updates. News includes facility builds, acquisitions, partnerships, and EU's Caribbean investment in pharma manufacturing.

Medicare use of GLP-1 diabetes drugs like Ozempic rose 900% over 5 years, with 2023 spending at $35.8B. HHS report shows ...